Amneal Pharmaceuticals, Inc. $AMRX Stock Holdings Lifted by Quantbot Technologies LP

Quantbot Technologies LP raised its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 124.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 268,805 shares of the company’s stock after purchasing an additional 149,272 shares during the quarter. Quantbot Technologies LP owned approximately 0.09% of Amneal Pharmaceuticals worth $2,253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Versor Investments LP purchased a new position in Amneal Pharmaceuticals in the first quarter valued at about $120,000. Algert Global LLC grew its stake in Amneal Pharmaceuticals by 25.7% in the first quarter. Algert Global LLC now owns 560,783 shares of the company’s stock valued at $4,699,000 after purchasing an additional 114,788 shares in the last quarter. Raymond James Financial Inc. grew its stake in Amneal Pharmaceuticals by 60.4% in the first quarter. Raymond James Financial Inc. now owns 596,502 shares of the company’s stock valued at $4,999,000 after purchasing an additional 224,506 shares in the last quarter. Sei Investments Co. grew its stake in Amneal Pharmaceuticals by 0.4% in the first quarter. Sei Investments Co. now owns 340,816 shares of the company’s stock valued at $2,710,000 after purchasing an additional 1,355 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Amneal Pharmaceuticals by 81.9% in the first quarter. Russell Investments Group Ltd. now owns 483,804 shares of the company’s stock valued at $4,035,000 after purchasing an additional 217,877 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $9.41 on Thursday. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $9.59. The stock has a market capitalization of $2.96 billion, a PE ratio of 941.94 and a beta of 1.11. The stock has a 50-day simple moving average of $8.31 and a 200 day simple moving average of $7.99.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AMRX shares. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a “buy” rating and a $12.00 price target for the company. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $11.60.

Insider Buying and Selling

In related news, EVP Andrew S. Boyer sold 33,436 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $302,595.80. Following the completion of the transaction, the executive vice president owned 256,670 shares of the company’s stock, valued at approximately $2,322,863.50. The trade was a 11.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nikita Shah sold 71,694 shares of the business’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $9.29, for a total value of $666,037.26. Following the transaction, the executive vice president directly owned 267,235 shares of the company’s stock, valued at $2,482,613.15. This represents a 21.15% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 177,130 shares of company stock valued at $1,619,733. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.